BioMedNewsBreaks

TuesdayJul 12, 2022 3:08 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Successful Completion of Phase I Single Ascending Dosing for Intranasal Concussion Drug

Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., a company focused on developing unique, life-enhancing medical products, today announced the completion of all three cohorts in its Phase I Single Ascending Dosing (“SAD”) clinical trial. According to the update, Odyssey’s trial involves administering PRV-002, the company’s novel drug to treat concussion, to healthy human subjects. Concussions represent an “unmet” medical need and affect millions worldwide, while a single concussion can significantly increase the risk of Alzheimer’s and other neuropsychiatric disorders. “After reviewing the data from Cohort III and completing the SAD analysis, I have strong confidence that PRV-002 will…

Continue Reading

MondayJul 11, 2022 11:44 am

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Acquires DMT Study Expected to Accelerate Clinical Development Path of CYB004

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that, through its wholly-owned subsidiary Cybin IRL Limited, it has completed the acquisition of a phase 1 N,N-dimethyltryptamine (“DMT”) study from Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1). The DMT study, which is the largest to date, is expected to accelerate the clinical development path of Cybin’s proprietary deuterated DMT molecule for the potential treatment of anxiety disorders, CYB004, by approximately nine months. “With the closing of this transaction, we are well on our way to advancing CYB004 through phase 1…

Continue Reading

FridayJul 08, 2022 2:54 pm

BioMedNewsBreaks – Silo Pharma Inc. (SILO) Bringing Hope, Possible Therapeutic to Alzheimer’s Patients

Silo Pharma (OTCQB: SILO) is committed to serving patients, families and caregivers worldwide struggling with Alzheimer’s Disease (“AD”). Last year, the company entered into a sponsored research agreement (“SRA”) with Columbia University to investigate and advance psychedelic therapeutics for AD. Silo Pharma CEO Eric Weisblum expressed encouragement on partnering with Columbia University and Dr. Christine Ann Denny, an associate professor of clinical neurobiology, saying: “To bring hope and possibly a therapeutic to patients suffering from Alzheimer’s Disease is an exciting proposition for Silo Pharma.” Alongside its work with Columbia University, Silo has partnered with Zylo Therapeutics to use Zylo’s Z-pod…

Continue Reading

FridayJul 08, 2022 10:58 am

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Moves One Step Closer to In-Human Trials with Completion of Preclinical Toxicity Study

Aditxt Inc. (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system, has successfully completed a toxicology study evaluating Adimune(TM), its proprietary therapeutic program. The study indicates the safety profile of ADI(TM)-100, ADTX’s immunotherapeutic technology drug, which is designed to treat the rejection of transplanted organs, skin allografting, autoimmune diseases and allergies. Calling the study results “promising,” the company noted that those results will provide vital supporting evidence when Aditxt moves forward with an investigational new drug (“IND”) application with the regulatory agencies. According to the announcement, ADI-100 is made of two DNA…

Continue Reading

ThursdayJul 07, 2022 1:24 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Poised to Successfully Commercialize Its Products

Odyssey Health (OTC: ODYY) is a Nevada-based medical company developing a variety of drug and technology assets to treat unmet clinical needs. “Odyssey is dedicated to advancing life-saving medical products that offer similar levels of hope to a new generation of people through technological and clinical developments that demonstrate advantages over current standards of care. At the moment, Odyssey’s market profile includes two medical device candidates and two pharmaceutical products in development. The portfolio is responding to varied needs, including patients who may have undiagnosed heart disease, patients choking on some type of obstruction lodged in their throats, patients dealing…

Continue Reading

FridayJul 01, 2022 1:03 pm

BioMedNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) AditxtScore(TM) Helping Individuals Make More Informed Decisions

Aditxt (NASDAQ: ADTX) recently partnered with Premier Medical Laboratory Services to provide individuals with personalized information regarding their immune system via the AditxtScore(TM). A recent article reads: “The AditxtScore can be used to provide those tested with important answers to questions like: Are antibodies present? How are these antibodies present – vaccine or natural immune system response? Will this immunity status provide protection from the virus in the future? What is the best approach to creating immunity for that individual?” Regarding the partnership, Kevin Murdock, CEO of Premier Medical Laboratory Services, commented, “As new variants emerge, we want to equip…

Continue Reading

WednesdayJun 29, 2022 11:56 am

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Completes Safety Evaluation of Cohort II for Novel Drug to Treat Concussion

Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., a company focused on developing unique, life-saving medical products, today announced positive safety findings from cohort II of its phase I clinical trial. According to the update, the trial involves administering PRV-002, Odyssey’s novel drug to treat concussion, to healthy human subjects. Cohort II data indicates that the drug was safe and well-tolerated. “PRV-002 continues to be well-tolerated as we increase the intranasal dose levels,” said Michael Redmond, CEO of Odyssey Health. “We look forward to completing phase I clinical trials and moving into a phase II/III to determine the efficacy…

Continue Reading

TuesdayJun 28, 2022 3:00 pm

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Pursuing Strategy Against COVID-19, Immune System-Related Maladies

Aditxt (NASDAQ: ADTX) is focused on developing and commercializing technologies to monitor and reprogram the immune system with the ultimate goal of improving patient outcomes for a variety of conditions. “Aditxt is joining the fight against the pandemic while pursuing a larger strategy against immune system-related maladies ranging from seasonal allergies to organ transplant rejection,” a recent article reads. “Aditxt’s first commercial product is an immune monitoring technology trademarked as AditxtScore(TM) for COVID-19, which is designed to provide users with a personalized profile of their immune status – specifically in relation to their vulnerability and immune response regarding COVID’s SARS-CoV-2…

Continue Reading

TuesdayJun 28, 2022 12:46 pm

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Adelia Announce Achievement of Milestone

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, a biotechnology company focused on progressing Psychedelics to Therapeutics(TM), and its wholly controlled subsidiary Adelia Therapeutics Inc., have announced the achievement of a key milestone. The milestone is identified as Y2, Q3 in the contribution agreement created between Adelia and Cybin when the company acquired Adelia. Reaching the milestone means that an estimated 37,366.2 class B common shares in Cybin will be issued to Adelia shareholders; the issuance of the shares represents the approximately $217,465 that Cybin agreed to pay if the key milestone was achieved. Adelia…

Continue Reading

MondayJun 27, 2022 2:10 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Releases Report of Annual General Meeting of Shareholders

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a life-sciences holding company dedicated to building a portfolio of assets and biotech solutions, is reporting on its annual general meeting of shareholders; the meeting was held online on June 23, 2022. During the meeting, seven nominees were elected as directors of the company. The new directors are Anthony Durkacz, Zeeshan Saeed, Donal Carroll, Adnan Bashir, Fernando Cugliari, Nitin Kaushal and Lawrence Latowsky; the directors will serve until the next annual meeting of shareholders or until successors are elected or appointed. During the meeting, shareholders also reappointed MNP LLP as the company…

Continue Reading